-- Indinavir/ritonavir less effective than lopinavir/ritonavir as first-line HAART in HIV-1-infected patients.
Immunovirological "outcomes and toxicities of HAART regimens, including Lopinavir (LPV)/ritonavir (r) and indinavir (IDV)/r," were compared in antiretroviral naive HIV-1 patients. Fifty-five and 52 patients, respectively, were selected to start LPV/r or IDV/r as first-line HAART, according to research in Italy.
"Immunovirological and metabolic parameters were recorded at baseline and every 3 months as were side effects, AIDS-defining events and deaths. Demographic characteristics and NRTIs included in the regimens were comparable," wrote M. Bongiovanni and colleagues.
"Both groups reached undetectable HIV-RNA plasma viremia" by the third month, which was maintained during follow-up. However, patients receiving IDV/r were less likely "to obtain virological success (RH: 0.46). Patients receiving IDV/r showed a greater increase of total cholesterol (P = 0.01). Three patients on LPV/r and 21 on IDV/r discontinued the drug for toxicity, leading to an 8.40 higher risk of discontinuation in the latter group," M. Bongiovanni and colleagues reported.
Results indicate that IDV/r is "less effective and more toxic than LPV/RTV as first-line HAART," concluded the investigators.
Bongiovanni and colleagues published the results of their research in Antiviral Research (Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects. Antiviral Res. 2004 Apr;62(1):53-6.
For additional information, contact M. Bongiovanni, University Milan, L Sacco Hospital Vialba, Institute Infection Diseases & Trop Med, Via GB Grassi 74, I-20157 Milan, Italy.
The publisher of the journal Antiviral Research can be contacted at: Elsevier Science BV, PO Box 211, 1000 AE Amsterdam, Netherlands.
The information in this article comes under the major subject areas of AIDS and HIV, Antiretroviral, Pharmaceutical & Drug Development and Toxicity.
This article was prepared by AIDS Weekly editors from staff and other reports.
Bongiovanni M, Bini T, Chiesa E, et al., "Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects", Antiviral Res. 2004 Apr;62(1):53-6
PubMED Related articles Search